Bank of Montreal Can Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Bank of Montreal Can bought a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 62,977 shares of the biotechnology company’s stock, valued at approximately $585,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Capital World Investors boosted its position in Grifols by 15.2% during the first quarter. Capital World Investors now owns 17,172,143 shares of the biotechnology company’s stock worth $200,571,000 after purchasing an additional 2,265,005 shares during the period. Brandes Investment Partners LP boosted its position in shares of Grifols by 33.4% in the first quarter. Brandes Investment Partners LP now owns 10,293,456 shares of the biotechnology company’s stock valued at $75,863,000 after acquiring an additional 2,576,798 shares during the period. Black Creek Investment Management Inc. boosted its position in shares of Grifols by 8.6% in the first quarter. Black Creek Investment Management Inc. now owns 7,522,380 shares of the biotechnology company’s stock valued at $55,440,000 after acquiring an additional 597,905 shares during the period. Pictet Asset Management SA boosted its position in shares of Grifols by 22.6% in the first quarter. Pictet Asset Management SA now owns 5,530,510 shares of the biotechnology company’s stock valued at $40,760,000 after acquiring an additional 1,019,392 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Grifols by 69.9% in the first quarter. Bank of America Corp DE now owns 4,274,707 shares of the biotechnology company’s stock valued at $31,505,000 after acquiring an additional 1,759,321 shares during the period. Institutional investors own 16.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. StockNews.com assumed coverage on Grifols in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Morgan Stanley cut Grifols from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Grifols presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Grifols Stock Up 0.4 %

Shares of GRFS stock opened at $9.40 on Thursday. Grifols, S.A. has a one year low of $6.50 and a one year high of $10.97. The stock has a fifty day moving average price of $8.88 and a 200 day moving average price of $9.14. The company has a quick ratio of 0.79, a current ratio of 2.56 and a debt-to-equity ratio of 1.24.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.